Hepatorenal syndrome MedDRA version: 8.1 Level: LLT Classification code 10019846 Term: Hepatorenal syndrome
Conditions
Interventions
Trade Name: NORADRENALINA TARTR
Pharmaceutical Form: Solution for infusion
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-
Trade Name: GLIPRESSINA
Pharmaceuti
Sponsors
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -All consecutive patients with hepaatorenal syndrome type 1 and 2 -Age between 18 and 75 years 3-Informed written consent 4-Absence of exclusion criteria Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: -Age 75 years -Hepatocellular caarcinoma -Active bacterial infection -Gaastrointestinaal bleeding within the previous week -Hearth and respiratory failure - Distal arteriopathy - History of CAD - Arterial hypertension
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Effects of noradrenalin vs terlipressin on systemic haemodynamics and renal function in patients with hepaatorenal syndrome. Tolerability. Cost-effectivess study.;Secondary Objective: 1. Hepatic function. 2. Vasoactive systems plasma renin activity, plasma aldosterone;Primary end point(s): renal function | — |
Countries
Italy
Outcome results
None listed